Wayne C. Koff To Present At Annual Vaccines: All Things Considered Conference, Washington, DC Nov. 8-9, 2010
Wayne C. Koff, Chief Scientific Officer and Senior Vice President of Research and Development (R&D) at the International AIDS Vaccine Initiative (IAVI.org), will bestow the keynote figure titled “Future Directions in AIDS Vaccine Development: The Decade Ahead” at the 8th Annual Vaccines: All Things Considered Conference to be held this year in Washington, DC attached Nov. 8-9, 2010 by GTCbio. Dr. Koff will discuss vaccine development in the decade ahead, which determination include human efficacy trials of novel vaccine candidates, the preferment of replicating viral vector based candidates to clinical trials, and continued progress towards identification of immunogens that elicit broadly neutralizing antibodies.
During the past few years, in that place has been incremental progress towards the development of a whole and effective HIV vaccine. These advances have included: the foremost demonstration of passport against HIV in human efficacy trials, identification of of recent origin and potentially more assailable targets in succession HIV onward account of vaccine designs to elicit broadly neutralizing antibodies, and demonstration of mastery of infection in rhesus monkeys immunized with novel viral vector based immunogens. Our laboratories at IAVI, together with our collaborators, have focused onward the challenges associated with designing effective vaccine candidates to elicit broadly neutralizing antibodies and cellular immune responses against HIV. Our immunogen design efforts to elicit broadly neutralizing antibodies have included:
1) screening of HIV+ subjects to identify the subset through tolerant and potent HIV-specific neutralizing antibodies;
2) identification of monoclonal antibodies (mAbs) from such subjects and determining, at the molecular flat, the target astringent sites onward HIV of of that kind mAbs; and
3) tricky and screening immunogens to imitated the binding sites of the mAbs through the goal of eliciting broadly neutralizing antibodies.
These efforts, have led to the identification of several HIV+ “elite neutralizers”, new of great size and potent monoclonal antibodies against HIV, and the screening of the first stock of candidate immunogens. Our efforts to design immunogens qualified of controlling HIV vitiation have focused on the development of replicating viral vector based immunogens, owing in large part to the failure of non-replicating vectors to provide any benefit with respect to curb of HIV taint e.g. suppression of viral cargo, in human efficacy trials. Our aim is to mimic the vigor conferred by the agency of live-attenuated SIV with vectors guarded with respect to human use. The choice and prioritization of vectors is based on our current hypotheses towards conducive to what cause live-attenuated SIV outperforms other vaccine strategies regarding prevention and command of SIV. These hypotheses include the persistent reply of the vector, targeting the gut-associated lymphoid tissues where SIV and HIV settle a beach-head in season post-infection, and finally the potential need to target the vector openly to CD4+ CCR5+ cells. The decade in opposition order suitable include full of common human feeling efficacy trials of tale vaccine candidates, the preferment of replicating viral vector based candidates to clinical trials, and continued progress towards identification of immunogens that elicit broadly neutralizing antibodies.
Dr. Wayne C. Koff oversees IAVI’s R&D programs focused on the development of a safe and effective AIDS vaccine. These programs embrace the Neutralizing Antibody, Control of HIV/Live Attenuated, and Vector Discovery consortia focused on HIV vaccine first sight, a global network of laboratories focused on AIDS vaccine discovery and development, a product development infrastructure that has successfully advanced multiple DNA and viral vector based HIV vaccine candidates to clinical trials, and a reticulated of partnerships in the developing world what one. collectively have undertaken Phase I/II safeness and immunogenicity trials, and clinical research studies to urge on AIDS vaccine development.
Also presenting at the Vaccines: All Things Considered Conference are prestigious organizations including International AIDS Vaccine Initiative, George Washington University, Yale University, Georgetown University, Albany Medical College, FDA, Merck, Baxter, Walter Reed Army Institute of Research, The Michigan Nanotechnology Institute for Medicine and Biological Sciences, Pfizer, Novartis, Duke University, and other leaders in the vaccine industry.
The 8th Annual Vaccines: All Things Considered Conference features many people new discoveries and changes be delivered of occurred within the last year that affects the vaccine industry. The colloquy examines vaccine development from basic research to marketing. We draw together researchers, manufacturers, executives, investors and government officials to interact and share their perspectives of the vaccine industry.
434 W. Foothill Blvd. Monrovia, CA 91016
Tel: (626) 256-6405
fax: (626) 256-6460
September 05 2010 03:33 am | Immune System